88 related articles for article (PubMed ID: 17481779)
1. Novel analogs of VIP with multiple C-terminal domains.
Dangoor D; Rubinraut S; Fridkin M; Gozes I
Peptides; 2007 Sep; 28(9):1622-30. PubMed ID: 17481779
[TBL] [Abstract][Full Text] [Related]
2. Novel extended and branched N-terminal analogs of VIP.
Dangoor D; Rubinraut S; Fridkin M; Gozes I
Regul Pept; 2006 Nov; 137(1-2):42-9. PubMed ID: 16962672
[TBL] [Abstract][Full Text] [Related]
3. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
[TBL] [Abstract][Full Text] [Related]
4. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
5. [Directed mutagenesis of human recombinant receptors of vasoactive intestinal peptide of VIP1 and VIP2 type. Difference in structure-activity relationship].
Nicole P; Du K; Couvineau A; Laburthe M
Gastroenterol Clin Biol; 1997; 21(5):365-9. PubMed ID: 9208011
[TBL] [Abstract][Full Text] [Related]
6. Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor.
Couvineau A; Rouyer-Fessard C; Laburthe M
Regul Pept; 2004 Dec; 123(1-3):181-5. PubMed ID: 15518910
[TBL] [Abstract][Full Text] [Related]
7. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
8. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability.
Dangoor D; Biondi B; Gobbo M; Vachutinski Y; Fridkin M; Gozes I; Rocchi R
J Pept Sci; 2008 Mar; 14(3):321-8. PubMed ID: 17924396
[TBL] [Abstract][Full Text] [Related]
9. Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors.
Udawela M; Christopoulos G; Tilakaratne N; Christopoulos A; Albiston A; Sexton PM
Mol Pharmacol; 2006 Jun; 69(6):1984-9. PubMed ID: 16531504
[TBL] [Abstract][Full Text] [Related]
10. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.
Ceraudo E; Tan YV; Couvineau A; Lacapere JJ; Laburthe M
Ann N Y Acad Sci; 2006 Jul; 1070():180-4. PubMed ID: 16888162
[TBL] [Abstract][Full Text] [Related]
11. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling.
Couvineau A; Tan YV; Ceraudo E; Lacapère JJ; Murail S; Neumann JM; Laburthe M
Ann N Y Acad Sci; 2006 Jul; 1070():205-9. PubMed ID: 16888167
[TBL] [Abstract][Full Text] [Related]
12. VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1.
El Zein N; Badran B; Sariban E
J Leukoc Biol; 2008 Apr; 83(4):972-81. PubMed ID: 18174366
[TBL] [Abstract][Full Text] [Related]
13. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.
Langer I; Gregoire F; Nachtergael I; De Neef P; Vertongen P; Robberecht P
Peptides; 2004 Feb; 25(2):275-8. PubMed ID: 15063009
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells.
Langlet C; Gaspard N; Nachtergael I; Robberecht P; Langer I
Peptides; 2004 Dec; 25(12):2079-86. PubMed ID: 15572195
[TBL] [Abstract][Full Text] [Related]
15. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.
Delgado M; Robledo G; Rueda B; Varela N; O'Valle F; Hernandez-Cortes P; Caro M; Orozco G; Gonzalez-Rey E; Martin J
Arthritis Rheum; 2008 Apr; 58(4):1010-9. PubMed ID: 18383379
[TBL] [Abstract][Full Text] [Related]
16. Potent and selective agonists of alpha-melanotropin (alphaMSH) action at human melanocortin receptor 5; linear analogs of alpha-melanotropin.
Bednarek MA; MacNeil T; Tang R; Fong TM; Cabello MA; Maroto M; Teran A
Peptides; 2007 May; 28(5):1020-8. PubMed ID: 17376561
[TBL] [Abstract][Full Text] [Related]
17. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning and functional expression of a VIP-specific receptor.
Zhou H; Huang J; Murthy KS
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G728-34. PubMed ID: 16959956
[TBL] [Abstract][Full Text] [Related]
19. Structure-function analysis of a series of novel GIP analogues containing different helical length linkers.
Manhart S; Hinke SA; McIntosh CH; Pederson RA; Demuth HU
Biochemistry; 2003 Mar; 42(10):3081-8. PubMed ID: 12627975
[TBL] [Abstract][Full Text] [Related]
20. The development of VIP-ellipticine conjugates.
Moody TW; Czerwinski G; Tarasova NI; Moody DL; Michejda CJ
Regul Pept; 2004 Dec; 123(1-3):187-92. PubMed ID: 15518911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
